论文部分内容阅读
目的研究肺炎链球菌(SPN)临床分离株的药物敏感性。方法选取临床标本分离,其中肺炎链球菌130株。按一般方法对各种标本进行分离和培养;使用纸片扩散法对细菌进行药物敏感性测定,包括万古霉素(VA)、利奈唑胺(LZD)、左氧氟沙星(LEV)、红霉素(E)、克林霉素(DA)、四环素(TE)、复方新诺明(SXT);使用E-test对青霉素(P)和头孢噻肟(CTX)的最低抑菌浓度(MIC)进行测定。结果 130株肺炎链球菌中,VA、LZD、CTX的耐药菌株分别为0、0、0株,中介菌株分别为0、0、0株,敏感菌株分别为130、130、130株,耐药率分别为0、0、0;P、LEV的耐药菌株分别为10、1株,中介菌株分别为5、4株,敏感菌株分别为115、125株,耐药率分别为7.69%、0.77%;TE、SXT、E、DA的耐药菌株分别为105、91、110、110株,中介菌株分别为8、9、10、7株,敏感菌株分别为17、30、10、13株,耐药率分别为80.77%、70.00%、84.62%、84.62%。结论肺炎链球菌对VA、LZD及CTX保持高度的敏感性,危重患者临床上可首先选用;对P、LEV保持一定的耐药性,临床上应结合细菌药敏试验选用;对TE、SXT、E、DA保持较高的耐药性,临床上可减少使用。了解肺炎链球菌对相关抗生素的耐药性,可为临床用药提供依据。
Objective To study the drug sensitivity of Streptococcus pneumoniae (SPN) clinical isolates. Methods Separation of clinical specimens, of which Streptococcus pneumoniae 130 strains. All kinds of specimens were isolated and cultured according to the general method. The drug susceptibility of bacteria was determined by disk diffusion method, including vancomycin (VA), linezolid (LZD), levofloxacin (LEV), erythromycin ), Clindamycin (DA), tetracycline (TE) and cotrimoxazole (SXT). The minimum inhibitory concentrations (MICs) of penicillin (P) and cefotaxime (CTX) were determined by E-test. Results Among the 130 Streptococcus pneumoniae strains, there were 0, 0 and 0 resistant strains of VA, LZD and CTX, respectively. There were 0, 0 and 0 isolates of the intermediate strains, and the susceptible strains were 130, 130 and 130, respectively The rates were 0, 0, 0 respectively; the resistant strains of P and LEV were 10 and 1, respectively. There were 5 and 4 isolates, respectively. The susceptible strains were 115 and 125, respectively. The resistance rates were 7.69% and 0.77 %, Respectively. The resistant strains of TE, SXT, E and DA were 105, 91, 110 and 110, respectively, and the intermediary strains were 8, 9, 10 and 7, respectively. The susceptible strains were 17, 30, Resistance rates were 80.77%, 70.00%, 84.62%, 84.62% respectively. Conclusions Streptococcus pneumoniae is highly sensitive to VA, LZD and CTX. Critically ill patients may be the first choice in clinical practice. For P and LEV, they should be resistant to some antibiotics. Clinically, E, DA to maintain a high resistance, can reduce the clinical use. To understand the antibiotic resistance of Streptococcus pneumoniae can provide evidence for clinical use.